Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-02-23
1997-05-13
Barts, Samuel
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514562, 514616, 564154, 558254, 562426, A61K 3121
Patent
active
056293437
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/US93/09137 filed Sep. 27, 1993.
BACKGROUND OF THE INVENTION
Novel N-(mercaptoacyl)peptidyl compounds of formula (I) are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, coronary thrombosis associated with atherosclerotic plaque rupture, and aneurysmal aortic disease. The matrix metalloendoproteinases are a family of zinc-containing proteinases including but not limited to stromelysin, collagenase, and gelatinase, that are capable of degrading the major components of articular cartilage and basement membranes. The inhibitors claimed herein may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to a permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation. ##STR1##
The disability observed in osteoarthritis (OA) and rheumatoid arthritis (RA) is largely due to the loss of articular cartilage. No therapeutic agent in the prior art is known to prevent the attrition of articular cartilage in these diseases.
"Disease modifying antirheumatic drugs" (DMARD), i.e., agents capable of preventing or slowing the ultimate loss of joint function in OA and RA are widely sought. Generic nonsteroidal antiinflammatory drugs (NSAIDs) may be combined with such agents to provide some relief from pain and swelling.
Stromelysin (aka. proteoglycanase, matrix metalloproteinase-3, MIMP-3, procollagenase activator, "transin"), collagenase (aka. interstitial collagenase, matrix metalloproteinase-1, MMP-1, Type II collagenase), and gelatinase (aka. type IV collagenase, matrix metalloproteinase-2, MMP-2, 72kDa-gelatinase or type V collagenase, matrix metalloproteinase-9, MMP-9, 95kDa-gelatinase) are metalloendoproteinases secreted by fibroblasts and chondrocytes, and are capable of degrading the major connective tissue components of articular cartilage or basement membranes. Elevated levels of both enzymes have been detected in joints of arthritic humans and animals: K. A. Hasty, R. A. Reife, A. H. Kang, J. M. Stuart, "The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis", Arthr. Rheum., 33,388-97 (1990); S. M. Krane, E. P. Amento, M. B. Goldring, S. R. Goldring, and M. L. Stephenson, "Modulation of matrix synthesis and degradation in joint inflammation", in The Control of Tissue Damage", A. B. Glauert (ed.), Elsevier Sci. Publ., Amsterdam, 1988, Ch. 14, pp 179-95; A. Blanckaert, B. Mazieres, Y. Eeckhout, G. Vaes, "Direct extraction and assay of collagenase from human osteoarthrtic cartilage", Clin. Chim. Acta, 185 73-80 (1989). Each enzyme is secreted from these cells as an inactive proenzyme which is subsequently activated. There is evidence that stromelysin may be the in vivo activator for collagenase and gelatinase, implying a cascade for degradative enzyme activity: A. Ho, H. Nagase, "Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase", Arch Biochem Biophys., 267,211-16 (1988); G. Murphy, M. I. Crockett, P. E. Stephens, B. J. Smith, A. J. P. Docherty, "Stromelysin is an activator of procollagenase", Biochem. J., 248, 265-8 (1987); Y. Ogata, J. J. Enghild, H. Nagase, "Matrix metalloproteinase 3 (stromelysin) activates the precursor for human matrix metalloproteinase 94, J. Biol. Chem., 267, 3581-3584 (1992). Inhibiting stromelysin could limit the activation of collagenase and gelatinase as well as prevent the degradation proteoglycan.
That stromelysin inhibition may be effective in preventing articular cartilage degradation has been demonstrated in vitro by measuring the effect of matrix metalloendoproteinase inhibitors on proteoglycan release from rabbit cartilage explants: C. B. Caputo, L. A. Sygowski, S. P. Patton, D. J. Wolanin, A. Shaw, R. A. Roberts, G. DiPa
REFERENCES:
patent: 5061710 (1991-10-01), Haslanger
Hagmann William
Kopka Ihor
Barts Samuel
Merck & Co. , Inc.
Panzer Curtis C.
Rose David L.
LandOfFree
N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1385732